High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: Structure-activity relationship of daunosamine-modified derivatives of doxorubicin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 93, Issue 6, 1996, Pages 2464-2469

  Nagy, Attila ^a   Armatis, Patricia ^a   Schally, Andrew V ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alkylating agents; Antineoplastic drugs; Cytotoxic agents; Design and synthesis; Steric factors

Indexed keywords

3' DEAMINO 3' (2 PYRROLIN 1 YL)DOXORUBICIN; BUTYRALDEHYDE; DAUNOSAMINE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; HALIDE; N,N DIMETHYLFORMAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN MCF 7; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALDEHYDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG DESIGN; HUMANS; MASS SPECTROMETRY; MICE; PYRROLES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0029965293     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.93.6.2464     Document Type: Article

References (24)

1. Di Marco, A., Gaetani, M., Orezzi, P., Scarpinato, B. M., Silvestrini, R., Soldati, M., Dasdia, T. & Valentini, L. (1964) Nature (London) 201, 706-707.
2. Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C. & Spalla, C. (1969) Biotechnol. Bioeng. 11, 1101-1110.
3. Weiss, R. B. (1992) Semin. Oncol. 19, 670-686.
4. Cummings, J. & Anderson, L. (1991) Eur. J. Cancer 27, 532-535.
5. Bristow, M. R., Thompson, P., Martin, R. P., Mason, J. W., Billingham, M. E. & Harrison, D. C. (1978) Am. J. Med. 65, 823-832.
6. Moscow, J. A. & Cowan, K. H. (1988) J. Natl. Cancer Inst. 80, 14-20.
7. Acton, E. M., Tong, G. L., Mosher, C. W. & Wolgemuth, R. L. (1984) J. Med. Chem. 27, 638-645.
8. Sikic, B. I., Ehsan, M. N., Harker, V. G., Friend, N. F., Brown, B. W., Newman, R. A., Hacker, M. P. & Acton, E. M. (1985) Science 228, 1544-1546.
9. Johnston, J. B., Hahernicht, B., Acton, E. M. & Glazer, R. I. (1983) Biochem. Pharmacol. 32, 3255-3258.
10. Streeter, D. G., Taylor, D. L. Acton, E. M. & Peters, J. H. (1985) Cancer Chemother. Pharmacol. 14, 160-164.
11. Jesson, M. I., Johnston, J. B., Anhalt, C. D. & Begleiter, A. (1987) Cancer Res. 47, 5935-5938.
12. Jesson, M. I., Johnston, J. B., Rohotham, E. & Begleiter, A. (1989) Cancer Res. 49, 7031-7036.
13. Cullinane, C. & Phillips, D. R. (1993) Nucleic Acids Res. 21, 1857-1862.
14. Zwelling, L. A., Altshuler, E., Cherif, A. & Farquhar, D. (1991) Cancer Res. 51, 6704-6707.
15. Cherif, A. & Farquhar, D. (1992) J. Med. Chem. 35, 3208-3214.
16. Lau, D. H. M., Lewis, A. D., Duran, G. E. & Sikic, B. I. (1991) Proc. Am. Assoc. Cancer Res. 32, 1970 (abstr.).
17. Lewis, A. D., Lau, D. H. M., Duran, G. E., Wolf, C. R. & Sikic, B. I. (1991) Proc. Am. Assoc. Cancer Res. 32, 1976 (abstr.).
18. Gao, Y.-G., Liaw, Y.-C., Li, Y.-K., van der Marel, G. A., van Boom, J. H. & Wang, A. H.-J. (1991) Proc. Natl. Acad. Sci. USA 88, 4845-4849.
19. Vogel, A. I. (1956) A Textbook of Practical Organic Chemistry, (Longmans, New York), 3rd Ed., p. 1061.
20. Reile, H., Birnböck. H., Bernhardt, G., Spruss, T. & Schönenberger, H. (1990) Anal. Biochem. 187, 262-267.
21. Davies, W. A. M., Jones, J. B. & Pinder, A. R. (1960) J. Chem. Soc., 3504-3512.
22. Bobbitt, J. M., Amundsen, L. H. & Steiner, R. I. (1960) J. Org. Chem. 25, 2230-2231.
23. Acton, E. M., Wasserman, K. & Newman, R. A. (1989) Antharcyclines and Anthracenedione Based Antitumor Agents: Morpholinyl Anthracyclines, ed. Lown, W. J. (Elsevier Science, Amsterdam), pp. 55-101.
24. Schally, A. V., Nagy, A., Szepeshazi, K., Pinski, J., Halmos, G., Armatis, P., Miyazaki, M., Comaru-Schally, A.-M, Yano, T. & Emons, G. (1996) in Treatment with GnRH Analogs: Controversies and Perspectives, ed. Filicori, M. (Parthenon, Carnforth, U.K.), pp. 33-44.